BioCardia, Inc. is a regenerative medicine enterprise, currently in the clinical development phase, dedicated to devising cell-based and cell-derived treatments for cardiac and pulmonary ailments. Its primary therapeutic offering is CardiAMP, an autologous mononuclear cell therapy system designed to address heart failure and persistent myocardial ischemia. In parallel, the company is advancing allogeneic cell therapies for various heart and lung diseases, including an investigational platform utilizing culture-expanded bone marrow-derived mesenchymal cells, which is presently in Phase I/II trials for ischemic heart failure. Beyond its therapeutic pipeline, BioCardia provides the Helix biotherapeutic delivery system, engineered to precisely inject treatments into the heart muscle via an internal helical needle, alongside Morph deflectable guides and sheaths. The company's operations are headquartered in Sunnyvale, California.